PRL-3 promotes breast cancer progression by downregulating p14<sup>ARF</sup>-mediated p53 expression

HUA XIE<sup>1</sup> and HAO WANG<sup>2</sup>

Departments of <sup>1</sup>Thoracic Oncology and <sup>2</sup>Breast Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R. China

Received January 17, 2016; Accepted June 23, 2017

DOl: 10.3892/ol.2017.7639

Abstract. Prior studies have demonstrated that phosphatase of regenerating liver-3 (PRL-3) serves an avital function in cell proliferation and metastasis in breast cancer. However, the molecular mechanisms underlying the function of PRL-3 in breast cancer remain unknown. PRL-3 expression was analyzed in 24 pairs of breast cancer and normal tissues using the reverse transcription-quantitative polymerase chain reaction assay. The results of the present study identified that the expression of PLR-3 in breast cancer tissues was increased 4.2-fold, compared with normal tissues. Notably, overexpression of PRL-3 significantly promoted the proliferation of cancer cells and inhibited endogenous p53 expression by downregulating the expression level of p14 alternate reading frame (p14<sup>ARF</sup>). In addition, decreased expression levels of PRL-3 resulted in decreased breast cancer cell proliferation and increased expression level of p14<sup>ARF</sup>. These results suggested that PRL-3 enhances cell proliferation by downregulating p14<sup>ARF</sup> expression, which results in decreased levels of p53. The results of the present study demonstrated that PRL-3 promotes tumor proliferation by affecting the p14<sup>ARF</sup>-p53 axis, and that it may serve as a prognostic marker for patients with breast cancer.

Phosphatase of regenerating liver-3 (PRL-3), also known as PTP4A3, is a member of the protein tyrosine phosphatase superfamily (3). Protein tyrosine phosphatases exert crucial functions in modulating cellular processes, including cell growth, cell cycle progression and apoptosis, by regulating a number of proteins (4,5). PRL-3 is associated with tumor proliferation and metastasis, and is overexpressed in various types of cancer, including colorectal (6) and gastric cancer (7,8), ovarian carcinoma (9,10), multiple myeloma (11) and squamous cell carcinoma of the uterine cervix (12). Wang et al (13) demonstrated that PRL-3 was overexpressed in breast cancer and predicts a poor clinical outcome for patients. In the present study, PRL-3 was identified to function in tumor proliferation by acting on the p14<sup>ARF</sup>-p53 axis, suggesting that PRL-3 may be involved in the tumorigenesis of breast cancer.

Materials and methods

Tissues specimens and cell lines. A total of 24 breast cancer and adjacent normal tissues were obtained from the Sichuan Cancer Hospital (Chengdu, China). The tissues from each individual were frozen in liquid nitrogen and stored at -80˚C until use. The tissues were fixed with 10% formalin overnight at room temperature and the fixed-tissues were embedded in paraffin. The 4-µm-thick sections of the tissues were validated using H&E staining and immunohistochemical detection. Briefly, sections were stained for nuclei with hematoxylin for 5 min at room temperature, and then sections were washed with tap water and counterstained with eosin for 1 min and washed. The following primary antibodies were used to perform immunohistochemistry: anti-estrogen receptor (cat. no. ab180900; dilution, 1:200; Abcam, Cambridge, UK), anti-progesterone receptor (cat. no. ab32085; dilution, 1:100; Abcam) and anti-HER2 (cat. no. ab194979; dilution, 1:200; Abcam). Briefly, sections were blocked using 2% PBS + bovine serum albumin for 15 min at room temperature. Subsequently, primary antibody incubation was performed overnight at 4˚C. Next, a biotinylated anti-rabbit immunoglobulin (Ig)G (cat. no. ab150088; dilution, 1:2,000; Abcam) was used as a secondary antibody. The antibody staining in the tissue sections was observed using a light microscope (magnification, x40). Written informed consent was obtained from all patients and all protocols were approved by the Sichuan Cancer Hospital Ethics Committee (Chengdu, China).

Introduction

Breast cancer is the most common type of invasive cancer in females worldwide (1). Despite diverse screening programs and novel therapeutic strategies implemented to markedly decrease mortality rates, the physiological mechanism underlying the pathogenesis of breast cancer remains unknown (2). Therefore, the identification of biomarkers is required to improve the early diagnosis of breast cancer and decrease cancer mortality rates.

Correspondence to: Dr Hao Wang, Department of Breast Surgery, Sichuan Cancer Hospital, 55 Renmin South Road, Chengdu, Sichuan 610041, P.R. China
E-mail: farocean214@126.com

Key words: breast cancer, phosphatase of regenerating liver-3, p53, p14 alternate reading frame
Two breast cancer cell lines (MDA-MB-231 and MCF-7) were purchased from the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) at 37˚C in a humidified chamber containing 5% CO₂.

**RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** TRizol® reagent (Invitrogen, Thermo Fisher Scientific, Inc.) was used to extract total RNA from the breast cancer tissues or two breast cancer cell lines (MDA-MB-231 and MCF-7) and subsequently reverse-transcribed into cDNA using a First Strand cDNA Synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol with the following temperature protocol: -25˚C for 10 min and then at 42˚C for 60 min, followed by 99˚C for 5 min and then cooling to 4˚C for 5 min. Subsequently, RT-qPCR was performed on the ABI 7500 Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with FastStart™ Universal SYBR® Green Master (ROX) reagents (Roche Diagnostics GmbH). The temperature protocols for the qPCRs were as follows: 95˚C for 10 min, 40 cycles of 95˚C for 30 sec (inactivation) and 56˚C for 1 min (annealing). A melt curve was constructed following each reaction and data were analyzed using a 7500 Fast System SDS (version 1.4.0.25; Applied Biosystems; Thermo Fisher Scientific, Inc.). The primer sequences for PRL-3 were as follows: Forward, 5'-CTTCTCACACTACACACC-3'; reverse, 5'-GTCTTTGTCGCTGTGGTGTGC-3'. The primer sequences for p14ARF were as follows: Forward, 5'-GGCAGATTTAGCTAAGTGCT-3' and reverse, 5'-GCCACATCGTAAGTGCT-3'. The primer sequences for GAPDH were as follows: Forward, 5'-ACGUGACGGUGUCAGGUTT-3' and antisense, 5'-GCCAGATTTAGCTAAGTGCT-3'. The primer sequences for pSilencer vector (Ambion; Thermo Fisher Scientific, Inc.) to construct pSilencer/Shr-PRL-3, and pSilencer/Shr-p14ARF. Empty vectors with a scramble shRNA sequence were used as a negative controls (pSilencer/NC). The shRNA sequences were as follows: PRL-3shRNA sense, 5'-ACGUGACGGUGUCAGGUTT-3' and antisense, 5'-GCCAGATTTAGCTAAGTGCT-3'; p14ARFshRNA sense, 5'-CCGATGAAAGAACCAGAG-3' and antisense, 5'-CTCTGCTGTTCTTCAATCGG-3'; and scrambled shRNA (pSilencer/NC) sense, 5'-UUUAUCCGAACGUCAUGCATGTGTTTGCT-3' and antisense, 5'-CCGATGAAAGAACCAGAG-3'. The transfection was performed with Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Briefly, MDA-MB-231 or MCF-7 cells were seeded into 12-well plates (3x10⁵ or 4x10⁵ cells/well) the day prior to transfection and then transfected with 100 nM constructed pcDNA3/PRL-3, pcDNA3, pSilencer/Shr-PRL-3, pSilencer negative control (pSilencer/NC) and pSilencer/Thr-p14ARF. At 48 h after transfection, the mRNA/protein were collected and subject to RT-qPCR (as aforementioned) and western blot analysis.

**Plasmid construction and transfection.** Total RNA was extracted from the MDA-MB-231 cells using TRizol buffer (Invitrogen; Thermo Fisher Scientific, Inc.). Then the reverse transcription was performed using a Transcript First Strand cDNA Synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's protocol with the following temperature protocol: 42˚C for 60 min and 70˚C for 5 min. The PCR program for the amplification of cDNA was started at 94˚C for 5 min, followed by 40 cycles at 94˚C for 30 sec, 58˚C for 30 sec, 72˚C for 5 min and completed with a final extension at 72˚C for 5 min. The amplified product and pcDNA3 vector (Invitrogen, Thermo Fisher Scientific, Inc.) were digested with EcoRI and XhoI enzymes to construct pcDNA3/PRL-3. The short hairpin (sh)RNAs against PRL-3 (target sequence, 5'-AAATATGCACCGTCTCTCCC-3') and p14ARF (target sequence, 5'-AGAAAAGGCGAGGAGGCTC-3') were annealed and cloned into the BamHI and HindIII restriction sites of the pcDNA3 plasmid. The plasmid sequences for PRL-3 were as follows: Forward, 5'-CTTCTCACACTACACACC-3'; reverse, 5'-GTCTTTGTCGCTGTGGTGTGC-3'; the primer sequences for p14ARF were as follows: Forward, 5'-CCGATGAAAGAACCAGAG-3' and antisense, 5'-CTCTGCTGTTCTTCAATCGG-3'; and scrambled shRNA (pSilencer/NC) sense, 5'-UUUAUCCGAACGUCAUGCATGTGTTTGCT-3' and antisense, 5'-CCGATGAAAGAACCAGAG-3'. The transfection was performed with Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Briefly, MDA-MB-231 or MCF-7 cells were seeded into 12-well plates (3x10⁵ or 4x10⁵ cells/well) the day prior to transfection and then transfected with 100 nM constructed pcDNA3/PRL-3, pcDNA3, pSilencer/Thr-PRL-3, pSilencer negative control (pSilencer/NC) and pSilencer/Thr-p14ARF. At 48 h after transfection, the mRNA/protein were collected and subject to RT-qPCR (as aforementioned) and western blot analysis.

**Western blot analysis.** Proteins were extracted from the cell lines using Radio-immunoprecipitation Assay lysis buffer (Thermo Fisher Scientific, Inc.) for 20 min at 4˚C with occasional agitation. Equal amounts of protein extracts (determined using the BCA method) were subjected to 10% SDS-PAGE and subsequently transferred to a polyvinylidene fluoride membrane (0.45 µm pore size; EMD Millipore, Billerica, MA, USA). Followed by blocking with 5% skimmed milk for 1.5 h at room temperature, the membrane was incubated with primary antibodies: PRL-3 (dilution, 1:500; cat. no. ab50276; Abcam), anti-p53 (dilution, 1:500; cat. no. ab31333; Abcam), anti-p14ARF (dilution, 1:500; cat. no. ab3642; Abcam) and anti-GAPDH antibody (dilution, 1:500; cat. no. SAB4300645-100UG; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 4˚C overnight and rinsed twice with PBS, followed by incubation with peroxidase-conjugated secondary anti-rabbit (dilution, 1:2,000; cat. no. ab6721; Abcam) or anti-mouse IgG antibodies (dilution, 1:2,000; cat. no. ab6709; Abcam) for 1 h at room temperature. The membranes were washed twice with PBS and incubated with ECL substrate (Amersham, GE Healthcare Life Sciences, Chicago, IL, USA) before visualization on X-ray film. The intensity of each band was analyzed with ImageJ software (NIH, USA) and the fold change was calculated relative to the negative control (pSilencer/NC).

**Figure 1.** PRL-3 expression in breast cancer and adjacent normal tissues. The results of quantitative polymerase chain reaction indicate that the expression of PRL3 is increased in breast cancer tissues compared with adjacent normal tissues. Data are presented as the mean ± standard deviation from triplicate procedures; *P<0.05. PRL-3, phosphatase of regenerating liver-3.
The membrane was subsequently incubated with an enhanced chemiluminescent substrate kit (Thermo Fisher Scientific, Inc.) and exposed to X-ray film. ImageJ (version 1.41; National Institutes of Health, Bethesda, MD, USA) was used for the quantitative analysis of band densities. GAPDH was used as a control (primers as aforementioned).

**Colony formation assay.** MDA-MB-231 and MCF-7 cells were seeded into 12-well plates (3x10⁵ or 4x10⁵ cells/well) the day prior to transfection and were then transfected with 100 nM constructed pcDNA3/PRL-3, pSilencer/ShR-PRL-3, pSilencer/ShR-p14ARF and corresponding controls (Psilencer/NC). After 2 weeks of culture, 0.2% crystal violet was used to stain the cell colonies at room temperature for 30 min. Subsequently, the colonies were counted using an inverted fluorescence microscope (magnification, x40; IX71; Olympus Corporation, Tokyo, Japan). Each experiment was performed in triplicate (1 colony, >50 cells) and images of MCF-7 or MDA-MB-231 cell colonies were captured.

**Figure 2. Function of PRL-3 in two breast cancer cell lines.** MCF-7 and MDA-MB-231 cells were transfected with pcDNA3/PRL3 or pcDNA3/shR-PRL3 and their corresponding controls. (A) The PRL-3 level was determined using quantitative polymerase chain reaction. (B) Western blot analysis of PRL-3 protein following transfection with pcDNA3/PRL3 or pcDNA3/shR-PRL3 and their corresponding controls. An MTS assay was performed to determine the proliferation of (C) MCF-7 and (D) MDA-MB-231 cells. A colony formation assay was performed to determine the proliferation of (E) MCF-7 and (F) MDA-MB-231 cells transfected with pcDNA3/PRL3 or pcDNA3/shR-PRL3 and their corresponding controls. The images of MCF-7 or MDA-MB-231 cell colonies were captured using a camera and GADPH was used as the loading control for western blot analysis. Data are presented as the mean ± standard deviation from triplicate procedures. *P<0.05, **P<0.01. PRL-3, phosphatase of regenerating liver-3; shR, short hairpin RNA.
**MTS assay to determine cell proliferation.** Transfected MDA-MB-231 and MCF-7 cell lines [(3-5) x10⁴ cells/well] were plated in 96-well plates for 48 and 72 h and subsequently, the proliferation was determined using the CellTiter 96® Aqueous cell proliferation assay kit (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocol. The absorbance was determined at a wavelength of 490 nm using a Tecan microplate reader (Tecan Group, Ltd., Mannedorf, Switzerland).

**Statistical analysis.** Experiments were performed in triplicate. The results are presented as the mean ± standard deviation. Differences between two groups were determined with unpaired Student's t-test using SPSS (version 12.0; SPSS, Inc., Chicago, IL, USA). One-way analysis of variance was used for multiple comparisons followed by a Bonferroni Comparison post hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**PRL-3 is overexpressed in breast cancer tissue samples.** RT-qPCR was performed to investigate the expression manner in the 24 pairs of breast cancer and adjacent non-cancerous tissues. The results of RT-qPCR identified that PRL-3 expression levels were significantly increased in the tumor tissues compared with adjacent normal tissues (P<0.05; Fig. 1).

**PRL-3 promotes the proliferation of breast cancer cells.** To determine whether PRL-3 affects cell proliferation, an MTS assay was performed using MCF-7 and MDA-MB-231 cells. First, overexpression of PRL-3 was achieved via transfection with pcDNA3/PRL-3, whereas the suppression of PRL-3 was achieved by transfection with pSilencer/PRL-3. RT-qPCR and western blot analysis was used to validate the efficiency of the vectors. The expression of PRL-3 mRNA was significantly increased in the pcDNA3/PRL-3 group while decreased in the pSilencer/PRL-3 group, compared with the control groups (P<0.05; Fig. 2A). The expression of PRL-3 protein was consistent with the expression of PRL-3 mRNA (P<0.01; Fig. 2B). An MTS assay results revealed that PRL-3 overexpression promoted cell proliferation 3.8- and 4.5-fold at 48 and 72 h post-transfection, respectively, compared with the control groups (P<0.05; Fig. 2C). Concordant with the results observed in the MCF-7 cell line, PRL-3 served a similar role in the MDA-MB-231 cell line (P<0.05; Fig. 2D).

To assess the effects of PRL-3 on cell growth, a colony formation assay was performed. Overexpression of PRL-3 in MCF-7 cells revealed a significant increase in the number of colonies, compared with the control group (P<0.05; Fig. 2E). Knockdown of PRL-3 (pSilencer/shR-PRL-3) in MCF-7 cells resulted in a significant decrease in the number of colonies, compared with the control group (Fig. 2E). In addition, a similar effect was observed in MDA-MB-231 cells (P<0.05; Fig. 2F). The results of the present study indicated that PRL-3 promotes the proliferation of breast cancer cell lines.

**PRL-3 negatively regulates p53 and p14ARF protein expression in MCF-7 cells.** As previous studies have demonstrated that PRL-3 was involved in the regulation of p53 and p14ARF (14-16), the present study aimed to determine the association between PRL-3, p53 and p14ARF in breast cancer cells. The results of the present study revealed that the overexpression of PRL-3 in MCF-7 cells resulted in an inhibited p53 expression (48% decrease) compared with the negative control, whereas the inhibition of PRL-3 promoted the level of p53 1.8-fold (P<0.05; Fig. 3A). The effect of PRL-3 on the expression level of p14ARF was investigated. The results demonstrated that p14ARF was downregulated when PRL-3 was overexpressed, whereas inhibition of PRL-3 promoted the level of p14ARF in MCF-7 cell lines (P<0.05; Fig. 3B).

**PRL-3 promotes cell proliferation via the p14ARF-p53 axis.** An MTS assay was performed to determine whether PRL-3 affected cell proliferation via p14ARF-p53 and the knockdown efficiency of pSilencer/shR-p14ARF was validated in MCF-7 cells. The RT-qPCR results demonstrated that the p14ARF expression levels in the pSilencer/shR-PRL-3 group decreased by ~70% (P<0.01; Fig. 4A). Suppression of p14ARF with pSilencer/shR-p14ARF (pSilencer/shR-p14ARF+pSilencer NC) promoted cell proliferation and inhibition of PRL-3 (pSilencer/shR-PRL-3+ pSilencer NC) lead to suppressed cell proliferation in comparison with 3x10³ or 4x10³ cells/well controls (pSilencer NC+ pSilencer NC). The promoted cell proliferation induced by suppression of p14ARF can be rescued by co-transfection with pSilencer/shR-PRL-3 (pSilencer/shR-p14ARF+ pSilencer/shR-PRL-3) (72 h, P<0.05; Fig. 4B). Furthermore, the colony formation assay was used to evaluate the effects of p14ARF and PRL-3 on cell proliferation. MCF-7 cells transfected with pSilencer/shR-p14ARF revealed a significant increase in the number of the colonies, whereas cells transfected with pSilencer/shR-PRL-3 revealed a significant decrease in the number of colonies compared with the control (pSilencer NC+ pSilencer NC). Additionally, promoted cell proliferation induced by the knockdown of p14ARF can be rescued by co-transfection with pSilencer/shR-PRL-3 (pSilencer/shR-p14ARF+ pSilencer/shR-PRL-3) (P<0.05; Fig. 4C).

To determine the function of p53 in PRL-3-induced cell proliferation, p53 protein expression was evaluated in human breast cancer cells. The results revealed that the p53 level was significantly decreased in cells transfected with pSilencer/shR-p14ARF while significantly increased in cells transfected with pSilencer/shR-PRL-3. The decreased expression of p53 induced by pSilencer/shR-p14ARF can be rescued by the knockdown of PRL-3 (P<0.05; Fig. 4D). Therefore, the results of the present study demonstrated that PRL-3 downregulated p53 by affecting the expression of p14ARF in the progression of breast cancer cell proliferation.

**Discussion**

PRL-3 has previously been identified as an oncogene (8). The present study hypothesized that PRL-3 participates in p53-dependent cell proliferation. The results of the present study suggested that PRL-3 promotes breast cancer progression via the p14ARF-p53 axis that is concordant with the hypothesis. In
Figure 3. Western blot analysis of p53 and p14ARF proteins in different groups. (A) The expression of p53 was decreased in cells transfected with pcDNA3/PRL3 while the expression of p53 was increased in cells transfected with pSilencer/shR-PRL-3; (B) The expression of p14ARF was decreased in cells transfected with pcDNA3/PRL3 while the expression of p14ARF was increased in cells transfected with pSilencer/shR-PRL-3. GAPDH was used as the loading control. Data are presented as the mean standard deviation from triplicate procedures. *P<0.05. ARF, alternate reading frame; PRL3, phosphatase of regenerating liver-3; shR, short hairpin RNA.

Figure 4. PRL3 promotes the proliferation of breast cancer cells via the p14ARF-p53 axis. (A) The p14ARF protein level in MCF-7 cells transfected with pcDNA3/shR-p14ARF or the control was determined using western blot analysis. (B) The proliferation of cells transfected with pcDNA3/shR-p14ARF or pcDNA3/shR-PRL3 and their corresponding controls was determined using an MTS assay. (C) Colony formation assay analysis of MCF-7 cells transfected with pcDNA3/shR-p14ARF or pcDNA3/shR-PRL3 and their corresponding controls. The clones were imaged using a camera. (D) The expression levels in cells transfected with pcDNA3/shR-p14ARF or pcDNA3/shR-PRL3 and their corresponding controls. GADPH was used as the loading control for the western blots. *P<0.05, **P<0.01. ARF, alternate reading frame; PRL-3, phosphatase of regenerating liver-3; shR, short hairpin RNA; NC, negative control.
addition, the results of the present study demonstrated that PRL-3 inhibits p53 and p14ARF protein expression, indicating that PRL-3 may serve a key function in breast cancer progression.

Previous studies have identified that PRL-3 is associated with breast tumor progression (15), which prompted the present study to investigate the function of PRL-3 in breast cancer through examining the mRNA levels of PRL-3 in breast cancer and adjacent normal tissues. The results of the present study revealed that the expression of PRL-3 was increased in breast tumors compared with adjacent normal tissues. p14ARF and p53 protein have been previously identified to function as tumor suppressors (16-18); in the present study, overexpression of PRL-3 resulted in decreased levels of p14ARF and p53 protein in breast cancer cell lines. Studies have demonstrated that p14ARF induces apoptosis to inhibit cancer progression and that it is downregulated during breast cancer progression (19-21). The results of the present study revealed that suppression of p14ARF promotes cell proliferation, which may be rescued by co-transfection with pSilencer/shR-PRL-3. Additionally, p14ARF has been identified to regulate the levels of p53 in breast cancer cells (22,23). In the present study, it was revealed that the suppression of p14ARF inhibits the expression of p53 in breast cancer cell lines. Furthermore, p53 is regulated by the expression of p14ARF (24-26) and PRL-3 (27), via mouse double minute 2 homolog. The results of the present study revealed that PRL-3 decreases the p14ARF-mediated expression of p53 in breast cancer cells. In summary, PRL-3 regulates the level of p14ARF in order to inhibit the expression of p53. These results may indicate an underlying molecular mechanism involved in breast cancer development, and enable the identification of novel therapeutic targets for breast cancer.

References

1. McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancer (Baltimore) 99: 1701-1709, 2002.
2. Youlend DR, Cramb SM, Dunn NA, Muller JM, Pyke CM and Baade PD: The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol Biomarkers Prev 21: 1036-1044, 2012.
3. Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bii C, Ong KO, Zeng Q and Chng W: The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. Mol Cancer 11: 72, 2012.
4. Stephens BJ, Han H, Gokhale V and Von Hoff DD: PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 4: 1653-1661, 2005.
5. Kato H, Sembia S, Miskad UA, Seo Y, Kasuga M and Yokozaki H: High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metastatic potential. Cancer Res 60: 7318-7328, 2000.
6. Moller DV, Aytes A, Paduliotes L, Martinez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J, Capella G and Villanueva A: PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer 99: 1718-1725, 2008.
7. Miskad UA, Sembia S, Kato H and Yokozaki H: Expression of PRL-3 phosphatase in human gastric carcinomas: Close correlation with invasion and metastasis. Pathobiology 71: 176-184, 2004.
8. Wang Z, Cai SR, He YL, Zhan WH, Zhang CH, Wu H, Peng JJ, Xu JB, Zhang XH, Wang L and Song W: Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J Cancer Res Clin Oncol 135: 1041-1046, 2009.
9. Polato F, Codegoni A, Frascio R, Perego P, Mangioni C, Saha S, Bardelli A and Borgmии M: PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11: 6835-6839, 2005.
10. Liu H, Ali-adarroos AQ, Wang H, Guo K, Li J, Zhang HF and Zeng Q: PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells. BMC Cancer 13: 80, 2013.
11. Fagerli UM, Holt RU, Holten T, Vaastuen TK, Zhan F, Engberg KW, Barlogie BA, Stone T, Aarsut H, Dai HY, et al: Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 111: 806-815, 2008.
12. Ma Y and Li B: Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix. Med Oncol 28: 775-780, 2011.
13. Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, Xie Y and Shou C: Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 17: 1517-1522, 2006.
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔCt) method. Methods 25: 402-408, 2001.
15. Ustusligoli BB, Bilici A, Barisik NO, Alissagudi M, Vardar FA, Yilmaz BE, Seker M and Gumus M: Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer. Clin Transl Oncol 14: 911-922, 2012.
16. Min L, Ma RL, Yuan H, Liu CY, Dong B, Zhang C, Zeng Y, Wang L, Guo JP, Qu LK and Shou CC: Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients. Asian Pac J Cancer Prev 16: 2819-2826, 2015.
17. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
18. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, JoSH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Corrigendum: Combined CSH and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 17: 1370, 2015.
19. Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spinrta R, Burkan RM, Strom BL, McDonald JA, Folger SG, et al: Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2 and p53 status. BMC Cancer 12: 235, 2012.
20. Milojkovic A, Hemmati PG, Miiter A, Overkamp T, Chumudi C, Jänicke RU, Gillissen B and Daniel PT: p14ARF induces apoptosis via an entirely caspase-3-dependent mitochondrial amplification loop. Int J Cancer 133: 2551-2562, 2013.
21. Silva J, Domínguez G, Silva JM, García JM, Gallego I, Corbacho C, Provenço M, España P and Bonilla F: Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 20: 4586-4590, 2001.
22. Maglic D, Zhu S, Fuy EA, Tanjea P, Kai F, Kendig RD, Sugiyama T, Miller LD, Williams MC and Inoue K: Prognostic value of the hDMPI-ARF-Hdm3-p53 pathway in breast cancer. Oncogene 32: 4120-4129, 2013.
23. Wazir U, Jiang WG, Yasaei H, Linne H, Newbold RF and Mokkel K: P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer. Anticancer Res 33: 2185-2189, 2013.
24. Xia L, Paik A and LiJJ: p53 activation in chronic radiation-treated breast cancer cells: Regulation of MDM2/p14ARF. Cancer Res 64: 221-228, 2004.
25. Wei J, Noto JM, Zaiha E, Romero-Gallo J, Piazzuelo MB, Schneider B, El-Rifai W, Correa P, Peek RM and Zaiha AI: Bacterial CagA protein induces degradation of p53 protein in a p14ARF-dependent manner. Gut 64: 1040-1048, 2015.
26. Wang J, Ding S, Duan Z, Xie Q, Zhang T, Zhang X, Wang Y, Chen X, Zhang H and Lu F: Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. Oncogene 35: 1692-1702, 2016.
27. Lv H, Liu R, Fu J, Yang Q, Shi J, Chen P, Ji M, Shi B and Hou P: Epithelial cell-derived peristin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rh/E2F1/p14ARF/Mdm2 signaling pathway. Cell Cycle 13: 2962-2974, 2014.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.